Lineage Cell Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Lineage Cell Therapeutics, Inc. (LCTX) reported Business Acquisition, Pro Forma Net Income (Loss) of $25.86 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2014-11-07
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2014-09-30 was $43.47M, a 35.57% decline year-over-year.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2014-06-30 was -$9.51M.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2014-03-31 was -$8.10M.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2013-12-31 was -$68.33M.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2013 was -$26.42M.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2012 was -$38.78M.
- Lineage Cell Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2011 was -$16.34M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | $43.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $33.96M derived: sum of 2 quarters · filed 2014-11-07 | $25.86M 10-Q · filed 2014-11-07 | -$42.47M derived: sum of 4 quarters · filed 2014-11-07 | ||||
| 2014-06-30 | -$9.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$17.61M 10-Q · filed 2014-08-11 | -$85.94M derived: sum of 3 quarters · filed 2014-08-11 | -$18.46M derived: sum of 4 quarters · filed 2014-11-07 | ||||
| 2014-03-31 | -$8.10M 10-Q · filed 2014-05-12 | -$76.43M derived: sum of 2 quarters · filed 2014-05-12 | -$8.95M derived: sum of 3 quarters · filed 2014-11-07 | -$11.95M derived: sum of 4 quarters · filed 2014-11-07 | ||||
| 2013-12-31 | -$68.33M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$855.24K derived: sum of 2 quarters · filed 2014-11-07 | -$3.85M derived: sum of 3 quarters · filed 2014-11-07 | -$26.42M 10-K · filed 2014-03-17 | ||||
| 2013-09-30 | $67.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $64.48M derived: sum of 2 quarters · filed 2014-11-07 | $41.90M 10-Q · filed 2014-11-07 | -$24.27M 10-Q · filed 2013-11-12 | -$12.17M derived: sum of 4 quarters · filed 2014-11-07 | |||
| 2013-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$25.57M 10-Q · filed 2014-08-11 | -$15.11M 10-Q · filed 2013-08-09 | -$79.64M derived: sum of 3 quarters · filed 2014-08-11 | -$54.02M derived: sum of 4 quarters · filed 2014-08-11 | |||
| 2013-03-31 | -$22.57M 10-Q · filed 2014-05-12 | -$7.72M 10-Q · filed 2013-05-10 | -$76.64M derived: sum of 2 quarters · filed 2014-05-12 | -$51.03M derived: sum of 3 quarters · filed 2014-05-12 | -$56.35M derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | -$54.07M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$28.46M derived: sum of 2 quarters · filed 2014-03-17 | -$33.78M derived: sum of 3 quarters · filed 2014-03-17 | -$38.78M 10-K · filed 2014-03-17 | -$21.32M 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $25.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $20.29M derived: sum of 2 quarters · filed 2013-11-12 | $15.29M 10-Q · filed 2013-11-12 | -$15.29M 10-Q · filed 2012-11-09 | $9.98M derived: sum of 4 quarters · filed 2013-11-12 | |||
| 2012-06-30 | -$5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$10.33M 10-Q · filed 2013-08-09 | -$15.63M derived: sum of 3 quarters · filed 2013-08-09 | -$19.09M derived: sum of 4 quarters · filed 2013-08-09 | ||||
| 2012-03-31 | -$5.01M 10-Q · filed 2013-05-10 | -$10.31M derived: sum of 2 quarters · filed 2013-05-10 | -$13.77M derived: sum of 3 quarters · filed 2013-05-10 | |||||
| 2011-12-31 | -$5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$8.76M derived: sum of 2 quarters · filed 2013-03-18 | -$16.34M 10-K · filed 2013-03-18 | |||||
| 2011-09-30 | -$3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$11.03M 10-Q · filed 2012-11-09 | ||||||
| 2011-06-30 | -$7.58M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |